ALDR has been the subject of several other reports. Zacks Investment Research lowered Alder Biopharmaceuticals from a hold rating to a sell rating in a research report on Thursday, January 11th. BMO Capital Markets boosted their target price on Alder Biopharmaceuticals to $26.00 and gave the stock an outperform rating in a research report on Tuesday, January 9th. Mizuho restated a buy rating and set a $32.00 target price on shares of Alder Biopharmaceuticals in a research report on Wednesday, November 8th. BidaskClub lowered Alder Biopharmaceuticals from a sell rating to a strong sell rating in a research report on Tuesday, December 19th. Finally, ValuEngine lowered Alder Biopharmaceuticals from a sell rating to a strong sell rating in a research report on Friday, February 2nd. Four equities research analysts have rated the stock with a sell rating, one has given a hold rating and eleven have issued a buy rating to the company. The company has a consensus rating of Hold and an average target price of $28.14.
Shares of Alder Biopharmaceuticals (NASDAQ ALDR) traded down $0.55 during mid-day trading on Monday, reaching $14.20. The company had a trading volume of 2,561,000 shares, compared to its average volume of 1,965,689. The firm has a market capitalization of $1,000.70, a price-to-earnings ratio of -2.65 and a beta of 2.60. Alder Biopharmaceuticals has a 1 year low of $8.60 and a 1 year high of $24.65.
Several institutional investors and hedge funds have recently modified their holdings of ALDR. SG Americas Securities LLC acquired a new position in shares of Alder Biopharmaceuticals in the 4th quarter valued at approximately $132,000. Jane Street Group LLC acquired a new position in shares of Alder Biopharmaceuticals in the 3rd quarter valued at approximately $184,000. Paloma Partners Management Co acquired a new position in shares of Alder Biopharmaceuticals in the 4th quarter valued at approximately $222,000. Teacher Retirement System of Texas acquired a new position in shares of Alder Biopharmaceuticals in the 4th quarter valued at approximately $231,000. Finally, Voya Investment Management LLC grew its position in shares of Alder Biopharmaceuticals by 8.4% in the 2nd quarter. Voya Investment Management LLC now owns 22,304 shares of the biopharmaceutical company’s stock valued at $255,000 after purchasing an additional 1,734 shares during the period. Institutional investors and hedge funds own 95.34% of the company’s stock.
Alder Biopharmaceuticals Company Profile
Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.
Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.